The Role of Biomarkers in Cardio-Oncology - 2020
Kajaluxy Ananthan, Alexander R. Lyon
AbstractIn the field of cardio-oncology, it is well recognised that despite the benefits of chemotherapy in treating and possibly curing cancer, it can cause catastrophic damage to bystander tissues resulting in a range of potentially of life-threatening cardiovascular toxicities, and leading to a number of damaging side effects including heart failure and myocardial infarction. Cardiotoxicity is responsible for significant morbidity and mortality in the long-term in oncology patients, specifically due to left ventricular dysfunction. There is increasing emphasis on the early use of biomarkers in order to detect the cardiotoxicity at a stage before it becomes irreversible. The most important markers of cardiac injury are cardiac troponin and natriuretic peptides, whilst markers of inflammation such as interleukin-6, C-reactive protein, myeloperoxidase, Galectin-3, growth differentiation factor-15 are under investigation for their use in detecting cardiotoxicity early. In addition, microRNAs, genome-wide association studies and proteomics are being studied as novel markers of cardiovascular injury or inflammation. The aim of this literature review is to discuss the evidence base behind the use of these biomarkers for the detection of cardiotoxicity.
Direct Left Atrial Pressure Monitoring in Severe Heart Failure: Long-Term Sensor Performance Tập 4 Số 1 - Trang 3-13 - 2011
Richard W. Troughton, Jay Ritzema, Neal Eigler, Iain Melton, Henry Krum, Philip B. Adamson, Saibal Kar, Prediman K. Shah, James S. Whiting, J. Thomas Heywood, Spencer Rosero, Jagmeet P. Singh, Leslie A. Saxon, Ray V. Matthews, Ian Crozier, William T. Abraham
Direct Reprogramming of Mouse Fibroblasts into Cardiac Myocytes Tập 6 - Trang 37-45 - 2012
Kohei Inagawa, Masaki Ieda
The potency of specific transcription factors as cell fate determinants was first demonstrated by the discovery of MyoD, a master gene for skeletal muscle transdifferentiation. More recently, the induction of pluripotency in somatic cells using a combination of stem cell-specific transcription factors has been reported. That elegant study altered the approach to regenerative medicine and inspired new strategies for generating specific cell types by introducing combinations of lineage-specific transcription factors. A diverse range of cell types, such as pancreatic β-cells, neurons, chondrocytes, and hepatocytes, can be induced from heterologous cells using lineage-specific reprogramming factors. Furthermore, functional cardiomyocytes can be generated directly from differentiated somatic cells using several combinations of cardiac-enriched defined factors in the mouse. The present article reviews the pioneering and recent studies in cellular reprogramming and discusses the perspectives and challenges of direct cardiac reprogramming in regenerative therapy.
